JP2017509628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509628A5 JP2017509628A5 JP2016556898A JP2016556898A JP2017509628A5 JP 2017509628 A5 JP2017509628 A5 JP 2017509628A5 JP 2016556898 A JP2016556898 A JP 2016556898A JP 2016556898 A JP2016556898 A JP 2016556898A JP 2017509628 A5 JP2017509628 A5 JP 2017509628A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- insr
- disorder
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 14
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims 11
- 102100036721 Insulin receptor Human genes 0.000 claims 11
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 5
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 5
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 3
- 102000003746 Insulin Receptor Human genes 0.000 claims 3
- 108010001127 Insulin Receptor Proteins 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 102000056713 human FGF21 Human genes 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 206010053857 partial lipodystrophy Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461950960P | 2014-03-11 | 2014-03-11 | |
| US61/950,960 | 2014-03-11 | ||
| PCT/US2015/019362 WO2015138278A1 (en) | 2014-03-11 | 2015-03-09 | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020094831A Division JP2020147583A (ja) | 2014-03-11 | 2020-05-29 | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509628A JP2017509628A (ja) | 2017-04-06 |
| JP2017509628A5 true JP2017509628A5 (cg-RX-API-DMAC7.html) | 2018-04-05 |
| JP6712230B2 JP6712230B2 (ja) | 2020-06-17 |
Family
ID=52682963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556898A Active JP6712230B2 (ja) | 2014-03-11 | 2015-03-09 | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
| JP2020094831A Pending JP2020147583A (ja) | 2014-03-11 | 2020-05-29 | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020094831A Pending JP2020147583A (ja) | 2014-03-11 | 2020-05-29 | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20170065678A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3125921B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6712230B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015138278A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
| US9006400B2 (en) | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
| JP7316946B2 (ja) * | 2017-07-06 | 2023-07-28 | イエール ユニバーシティ | 内分泌型ｆｇｆ関連疾患を処置または防止するための組成物および方法 |
| RS65720B1 (sr) * | 2017-12-22 | 2024-08-30 | Novartis Ag | Tretiranje metaboličkih poremećaja pomoću fgf21 varijanti |
| EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| NZ537208A (en) * | 2002-06-27 | 2009-02-28 | Adipogen Pharmaceuticals Pty Ltd | Differentiation modulating agents and uses therefor |
| UA87458C2 (ru) | 2003-06-12 | 2009-07-27 | Елі Ліллі Енд Компані | Гибридные белки-аналоги glp-1 |
| SI1641483T1 (sl) | 2003-06-12 | 2008-08-31 | Lilly Co Eli | Fuzijski proteini |
| CN1901908A (zh) * | 2003-11-04 | 2007-01-24 | 伊利舍医药品公司 | 治疗性化合物及其用途 |
| BRPI0416683A (pt) | 2003-12-10 | 2007-01-30 | Lilly Co Eli | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 |
| WO2005074916A1 (en) * | 2004-01-29 | 2005-08-18 | Applied Research Systems Ars Holding N.V. | Methods and compositions for the treatment of lipodystrophy |
| DE602005016917D1 (de) | 2004-05-13 | 2009-11-12 | Lilly Co Eli | Fgf-21-fusionsproteine |
| ES2566670T3 (es) | 2004-10-29 | 2016-04-14 | Ratiopharm Gmbh | Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF) |
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| US20110034373A1 (en) | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| US20110015345A1 (en) | 2008-03-19 | 2011-01-20 | Ambrx, Inc. | Modified FGF-23 Polypeptides and Their Uses |
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| SG195542A1 (en) | 2008-10-10 | 2013-12-30 | Amgen Inc | Fgf21 mutants and uses thereof |
| ES2692495T3 (es) | 2009-01-23 | 2018-12-03 | Novo Nordisk A/S | Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos |
| JP2012525847A (ja) | 2009-05-05 | 2012-10-25 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| UY38740A (es) | 2009-05-05 | 2020-12-31 | Amgen Inc | Mutantes de fgf21 y usos del mismo |
| WO2011154349A2 (en) | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| MX368790B (es) | 2009-10-15 | 2019-10-16 | Genentech Inc | Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada. |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| EP2359843A1 (en) | 2010-01-21 | 2011-08-24 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| EP2526117B1 (en) | 2010-01-22 | 2015-05-06 | Novo Nordisk A/S | Process for preparing fgf-21 with low degree of o-glycosylation |
| AU2011239689A1 (en) | 2010-04-15 | 2012-11-08 | Amgen Inc. | Human FGF receptor and beta-Klotho binding proteins |
| CN103415300B (zh) | 2010-07-20 | 2018-02-23 | 诺沃—诺迪斯克有限公司 | N‑末端修饰的fgf21化合物 |
| AU2011305306C1 (en) | 2010-09-22 | 2016-02-18 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| CA2815967A1 (en) | 2010-11-05 | 2012-05-10 | Covx Technologies Ireland Limited | Anti-diabetic compounds |
| US9023791B2 (en) * | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| EP2392927A1 (en) * | 2011-03-11 | 2011-12-07 | F. Hoffmann-La Roche AG | Diagnosis of metabolic disorders in HIV infected patients |
| WO2012177481A2 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
| US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
| EP2548570A1 (en) | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| WO2013033452A2 (en) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
| US9006400B2 (en) | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
| AR087973A1 (es) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| AR092076A1 (es) | 2012-08-22 | 2015-03-18 | Lilly Co Eli | Proteinas homodimericas |
| BR112015004734A2 (pt) | 2012-09-07 | 2017-11-21 | Sanofi Sa | proteínas de fusão para tratar uma síndrome metabólica |
| WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| DK2938740T3 (da) | 2012-12-27 | 2022-06-20 | Ngm Biopharmaceuticals Inc | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser |
| WO2014149699A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Bifunctional protein |
| WO2015148708A1 (en) | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Fgf21 receptor agonists and uses thereof |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016048999A2 (en) | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf21 truncations and mutants and uses thereof |
| UY36370A (es) | 2014-10-24 | 2016-04-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Polipéptidos fgf-21 modificados y sus usos |
-
2015
- 2015-03-09 JP JP2016556898A patent/JP6712230B2/ja active Active
- 2015-03-09 US US15/124,877 patent/US20170065678A1/en not_active Abandoned
- 2015-03-09 EP EP15710087.6A patent/EP3125921B1/en active Active
- 2015-03-09 WO PCT/US2015/019362 patent/WO2015138278A1/en not_active Ceased
-
2019
- 2019-05-09 US US16/407,813 patent/US11963999B2/en active Active
-
2020
- 2020-05-29 JP JP2020094831A patent/JP2020147583A/ja active Pending
-
2024
- 2024-03-19 US US18/609,420 patent/US20240293508A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509628A5 (cg-RX-API-DMAC7.html) | ||
| GT201600263A (es) | Ácidos grasos novedosos y su uso en la conjugación con biomoléculas | |
| HRP20211575T1 (hr) | Fuzijski proteini za liječenje metaboličkih poremećaja | |
| JP6379300B2 (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| Hassan et al. | Evolution and clinical translation of drug delivery nanomaterials | |
| CY1123307T1 (el) | Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
| JP2014526441A5 (cg-RX-API-DMAC7.html) | ||
| WO2013009545A8 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| JP2014500880A5 (cg-RX-API-DMAC7.html) | ||
| JP2016532690A5 (cg-RX-API-DMAC7.html) | ||
| CL2007002347A1 (es) | Compuestos derivados de fenilo, piridina y quinolina; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de diabetes mellitus, trastornos en la tolerancia de la glucosa, obesidad, enfermedad de crohn, enferm | |
| AR083920A1 (es) | Metodos de tratamiento de trastornos asociados con el fgf21 (factor de crecimiento de fibroblastos 21) | |
| EP4306165A3 (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases | |
| JP2014530220A5 (cg-RX-API-DMAC7.html) | ||
| BR112014032526A2 (pt) | composto, e composição farmacêutica | |
| JP2016503770A5 (cg-RX-API-DMAC7.html) | ||
| FI3452507T3 (fi) | Tau-immuunihoito | |
| JP2016513730A5 (cg-RX-API-DMAC7.html) | ||
| WO2016109823A8 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| JP2017507142A5 (cg-RX-API-DMAC7.html) | ||
| RU2010113994A (ru) | Применение панкреатического полипептида человека в качестве терапевтического средства | |
| JP2016515123A5 (cg-RX-API-DMAC7.html) | ||
| JP2010500284A5 (cg-RX-API-DMAC7.html) | ||
| MX2022007929A (es) | Coagonistas de triazol grapados de los receptores de glucagon y glp-1. | |
| JP2016526533A (ja) | アミリンミメティック化合物とポリエチレングリコールの非凝集バイオ接合体 |